Rodman & Renshaw launched coverage of BioRestorative Therapies (NASDAQ:BRTX) with a “buy” rating and $15 target price. The stock closed at $2.02 on June 26. BioRestorative develops therapeutic products using cell...
Elemer Piros Elemer Piros has rejoined the healthcare research team at Roth Capital Partners as managing director, senior research analyst covering biotechnology. His research coverage is expected to include small...